Over 20 million Americans are diabetic and the incidence is increasing by 5% per year. The most common complication of diabetes is neuropathy (DN) which occurs in approximately 60% of diabetic patients (Vincent and Feldman, 2004). In the United States, DN is the leading cause of diabetes-related hospital admissions and nontraumatic amputations (Boulton et al., 2005) (http://www.diabetes.org).
Introduction
Over 20 million Americans are diabetic and the incidence is increasing by 5% per year. The most common complication of diabetes is neuropathy (DN) which occurs in approximately 60% of diabetic patients (Vincent and Feldman, 2004) . In the United States, DN is the leading cause of diabetes-related hospital admissions and nontraumatic amputations (Boulton et al., 2005) (http://www.diabetes.org).
There are no accepted treatments for DN beyond glucose control. In part, the lack of effective therapies stems from the lack of animal models of DN. The Animal Models of Diabetic Complications Consortium (AMDCC) was formed by the NIH to develop new animal models of diabetic complications; its goal is to identify the most appropriate animal models to study the etiology, prevention and treatment of diabetic complications, including DN.
The most useful mouse model of DN should exhibit the key features present in human pathology (Feldman et al., 2003) including (1) sensory loss, (2) electrophysiological measures of nerve impairment and (3) anatomical evidence of nerve fiber loss. Neuropathy phenotyping begins with evaluation of sensory loss by quantitative assessment of thermal sensitivity. Electrophysiological measures of nerve impairment are the "gold standard" for determining sensory and motor nerve function and include assessment of motor and sensory nerve conductions in the tail and sciatic nerve. Finally, analysis of the number of small fibers in the mouse footpad lends insight into function. Anatomical evidence of nerve fiber loss is measured by assessment of intraepidermal nerve fiber (IENF) density in the footpad.
The current study examined DN in 4 inbred strains of mice. Our goal was to identify mouse models that closely resemble neural changes present in patients with DN. We hypothesize that development of DN is multifactorial and is influenced by background strain and diet. We determined that the most robust model for DN was the db/db mouse on the C57BLKS background. This model remained hyperglycemic without dietary intervention and developed progressive loss of sensory function, slowed nerve conductions and loss of intraepidermal nerve fibers. Our finding that the development of DN varies across mouse models of diabetes agrees with the recent report by Qi et al. (Qi et al., 2005) . Abbreviations: AMDCC, Animal Models of Diabetic Complications Consortium; DRG, dorsal root ganglia; DN, diabetic neuropathy; GHb, glycated hemoglobin; IENF, intraepidermal nerve fiber; IHC, immunohistochemistry; NCV, nerve conduction velocity; NT, nitrotyrosine; PGP9.5, protein gene product 9.5, ubiquitin C-terminal hydrolase; PLP, paraformaldehyde, lysine and sodium periodate; SMNCV, sciatic-tibial motor nerve conduction velocity; STZ, Streptozotocin; TDML, Tail motor distal latency; TSNCV, Tail sensory nerve conduction velocity; TUNEL, TdT-mediated dUTP-biotin nick end labeling.
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